Frontier Biology announced that the company has reached an investment intention with Doerr Pharmaceutical, intending to transfer 70% of the equity of Shanghai Jianhong to Doerr Pharmaceutical or its controlled entity. Shanghai Jianhong holds 100% equity of Sichuan Frontier, which is a high-end peptide active pharmaceutical ingredient production base invested and built by the company in Jintang County, Chengdu City, Sichuan Province. This transaction does not constitute a related-party transaction nor a major asset restructuring. The transaction plan and consideration still need to be determined through comprehensive financial audits and asset evaluations of the target company and negotiations between the two parties. If the two parties formally sign an equity transfer agreement for this transaction in the future, they will also need to fulfill the corresponding deliberation and decision-making procedures and obtain the approval of the competent regulatory authorities (if applicable) in accordance with the requirements of laws and regulations.